Company Profile

Cellectis S.A. (NASDAQ: CLLS)
4:30 PM EDT, 04/26/24
Last: $2.51 Change: +0.02 %Change: +0.63% Volume: 223,279
Detailed Quote
Open: $ 2.49   Volume: 223,279
High: $ 2.51   Yield(%) 0.00
Low: $ 2.35   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 178.66M
EPS ($) -1.68   Shares Out: 71.75M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -6.04
% Price Change (last 13 weeks): -9.78
% Price Change (last 26 weeks): 147.76
% Price Change (last 52 weeks): 28.35
% Price Change (year to date): -19.16
Management Effectiveness
Return on Equity (%): -53.52
Return on Assets (%): -28.23
Return on Invested Capital (%): -29.64
Profitability
Gross Profit Margin (%): 3.44
Net Profit Margin (%): -473.60
Operating Profit Margin (%): -509.08
Price & Volume
50-day Moving Average: $2.62
200-day Moving Average: $2.40
Avg. Daily Vol. (last 50 days): 40,986
Avg. Daily Vol. (last 200 days): 638,094
52-wk high: $3.77
52-wk low: $0.96
Bid: $2.40
Ask: $2.70
Company Information
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Cellectis S.A.
8, rue de la Croix Jarry
Paris IF 75013

Phone: 33.1.81.69.16.00
Fax: 33.1.81.69.16.06
http://www.cellectis.com
Per Share Data
Earnings (1year) ($): -1.68
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 2.58
Cash Flow ($): -1.92
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 4.99
Price/Book (x): 0.81
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 2.54
Current Ratio (x): 2.54
LT Debt/Equity (x): 53.34
Total Debt/Equity (x): 64.23



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.